Efti and chemo combo patent very important. If AIPAC phase 2b trial results are positive and referring to Goetz report April 2019 - conditional marketing approval in Europe 2020 and America a year later. Licensing deal with big Pharma - but who?
Paclitaxel (derived from bark of Pacific yew tree) is a generic chemo product and the only Paclitaxel registered brand I could find is Taxol which is owned by BMS.
Therefore BMS would be in pole position in a possible licensing deal - for Efti/Paclitaxel in breast cancer combo treatment only!
Leaving the door wide open for other Efti/chemo combinations and collaborations.
Well done Immutep team in gaining European patent. Another big tick in the business acumen box.
Ann: Immutep granted European patent for eftilagimod alpha, page-5
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
30.5¢ |
Change
0.010(3.39%) |
Mkt cap ! $443.0M | |||
| Open | High | Low | Value | Volume |
| 30.0¢ | 31.3¢ | 29.5¢ | $1.849M | 6.080M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 240592 | 29.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 31.0¢ | 110772 | 3 |
View Market Depth
| Last trade - 16.10pm 23/07/2024 (20 minute delay) ? |
| IMM (ASX) Chart |